成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 55750-63-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 55750-63-5
Chemical Structure| 55750-63-5
Structure of 55750-63-5 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 55750-63-5 ]

Related Doc. of [ 55750-63-5 ]

Alternatived Products of [ 55750-63-5 ]
Product Citations

Product Details of [ 55750-63-5 ]

CAS No. :55750-63-5 MDL No. :MFCD00043043
Formula : C14H16N2O6 Boiling Point : No data available
Linear Structure Formula :- InChI Key :VLARLSIGSPVYHX-UHFFFAOYSA-N
M.W : 308.29 Pubchem ID :5091655
Synonyms :
6-Maleimidocaproic Acid NHS; EMCS; MDTF
Chemical Name :2,5-Dioxopyrrolidin-1-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate

Calculated chemistry of [ 55750-63-5 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 22
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.5
Num. rotatable bonds : 8
Num. H-bond acceptors : 6.0
Num. H-bond donors : 0.0
Molar Refractivity : 80.42
TPSA : 101.06 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -8.54 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.07
Log Po/w (XLOGP3) : -0.51
Log Po/w (WLOGP) : -0.68
Log Po/w (MLOGP) : 0.31
Log Po/w (SILICOS-IT) : 0.67
Consensus Log Po/w : 0.37

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.9
Solubility : 38.6 mg/ml ; 0.125 mol/l
Class : Very soluble
Log S (Ali) : -1.14
Solubility : 22.1 mg/ml ; 0.0717 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.56
Solubility : 8.55 mg/ml ; 0.0277 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 3.01

Safety of [ 55750-63-5 ]

Signal Word:Warning Class:
Precautionary Statements:P261-P305+P351+P338 UN#:
Hazard Statements:H302-H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 55750-63-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 55750-63-5 ]

[ 55750-63-5 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 55750-63-5 ]
  • [ 1115-74-8 ]
  • [ 1342211-31-7 ]
YieldReaction ConditionsOperation in experiment
97% With triethylamine; In N,N-dimethyl-formamide; at 20℃; 150 mg (0.797 mmol) of <strong>[1115-74-8]L-valyl-L-alanine</strong> and 246 mg (0.797 mmol) of 1-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-6-oxohexyl}-1H-pyrrole-2,5-dione were dissolved in 4.0 ml of dimethylformamide, and 0.220 ml (1.6 mmol) of triethylamine was added. The reaction mixture was stirred at RT overnight. The reaction mixture was purified directly by preparative RP-HPLC (column: Reprosil 250*30; 10mu, flow rate; 50 ml/min, MeCN/water). The solvents were evaporated under reduced pressure and the residue was dried under high vacuum. This gave 302 mg (97% of theory) of N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) hexanoyl]-<strong>[1115-74-8]L-valyl-L-alanine</strong>. LC-MS (Method 12): Rt=1.02 min; MS (ESIpos): m/z=382 (M+H)+. 1H-NMR (400 MHz, DMSO-d6): delta [ppm]=0.82 (dd, 6H), 1.17 (m, 2H), 1.27 (d, 3H), 1.48 (m, 4H), 1.94 (m, 1H), 2.13 (m, 2H), 3.38 (t, 2H), 4.17 (m, 2H), 7.00 (s, 2H), 7.75 (d, 1H), 8.19 (d, 1H).
70% With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃;Inert atmosphere; Maeilimidocaproy. N-hydroxysuccinimide (1.619 g, 5.25 mmo., 105 eq.) and H-Val-Aia-OH (0,941 g, 5 mmol, 1 eq.) were placed in a 25 ml recovery fiask with a stir bar and the flask was flushed with nitrogen, DMF (4,7 mL) was added and the resulting white siurry was stirred. DIPEA (0.87 mL, 5 mmol, 1 eq) was added and the mixture was allowed to stir at room temperature overnight. The mixture was coo.ed in an ice/water bath and 2M HCI (3 mL, 6 mmol) was added dropwise. The viscous mixture was transferred to a separator/ funnel and the reaction vessel rinsed with sat. NaCl (7 mL), EtOAc (10 mL), sat NaCl {10 mL) and EtOAc (5 mL). After separation of the aqueous phase, it was extracted with additionai EtOAc {2 x 15 mL). The combined organic extracts were washed with sat NaCi {4 x 15 mL), until the washings were pH ~3,5. The organic extracts were dried over Na2S04, filtered and concentrated under reduced pressure to give crude 5 as a white solid (2,1 2 g, 114% crude yield). Crude 5 was suspended in warm CHjCIa {35 mL) and filtered to remov a fine white solid. The solids wer rinsed with additional CHjCi2 (3 mL). Toiuene {5mL) was added and the mixture was cooled in an ice/water bath, which resulted in a thick siurry. The solids were collected by filtration, washed with a cold mixture of CHjC (12 mL) and toluene (2 mL) and dried by puiilng air through the sample overnight to give 5 as a White solid (1 ,327 g, 70% yield). TLC: Rf = 0.26, 10% MeOH in CH2CI2. 1 H NMR (CDCI3)(ppm) 0.95 {d, J - 17 Hz, 3H), 0.98 (d, J - 17 Hz, 3H), 1.30 (m, 2H), 1.40 (d, J = 17 Hz, 3H), 1.61 (m, 4H), 2.06 (m, 1 H), 2.25 (dt, J = 4, 19 Hz, 2H). 3.35 (s, 1 H), 3.49 (t, J - 17 Hz,2H), 4.20 (d, J = 18 Hz, 1 H), 4.38 (m, 1 H), 6.80 {s, 2H). Analytical HPLC (0.1% formic acid): tR 9.05 min. LC-MS: tR 11.17 min, m/z (ES+) found 381.9 (M+H)+, m/z (ES-) found 379.9 (M-H)-.
52% In N,N-dimethyl-formamide; at 20℃; for 48h; (a) (S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3- methylbutanamido)propanoic acid (23)A suspension of dipeptide (22) (0.1 g, 0.54 mmol, 1 eq.) and 6-maleimidohexanoic acid succinimide ester (0.165 g, 0.54 mmol, 1 eq.) in anhydrous DMF (5 mL) was stirred at room temperature for 24 hours at which time LCMS indicated 50% conversion to a new product. The reaction mixture was diluted with anhydrous DMF (5 mL) and the reaction was allowed to continue for a further 24 hours. The solvent was evaporated under reduced pressure to give a colourless residue. Diethyl ether (60 mL) was added and the mixture was sonicated for 5 min, the ether was decanted and the process was repeated (x 2). The final ethereal portion was filtered to isolate the product (23) as a white powder which was dried under vacuum (0.105 g, 52%). Analytical Data: RT 2.28 min; MS (ES+) m/z (relative intensity) 382 ([M + H]+ , 90), MS (ES") m/z (relative intensity) 380 ([M - H])-, 100).
With triethylamine; 150 mg (0.797 mmol) of <strong>[1115-74-8]L-valyl-L-alanine</strong> and 246 mg (0.797 mmol) of 1-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-6-oxohexyl}-1H-pyrrole-2,5-dione were dissolved in 4.0 ml of dimethylformamide, and 0.220 ml (1.6 mmol) of triethylamine were added. The reaction mixture was stirred at RT overnight. The reaction mixture was purified directly by preparative RP-HPLC (column: Reprosil 250*30; 10mu, flow rate: 50 ml/min, MeCN/water). The solvents were evaporated under reduced pressure and the residue was dried under high vacuum. This gave 302 mg (97% of theory) of N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-<strong>[1115-74-8]L-valyl-L-alanine</strong>. LC-MS (Method 12): Rt=1.02 min; MS (ESIpos): m/z=382 (M+H)+. 1H-NMR (400 MHz, DMSO-d6): delta [ppm]=0.82 (dd, 6H), 1.17 (m, 2H), 1.27 (d, 3H), 1.48 (m, 4H), 1.94 (m, 1H), 2.13 (m, 2H), 3.38 (t, 2H), 4.17 (m, 2H), 7.00 (s, 2H), 7.75 (d, 1H), 8.19 (d, 1H).

Recommend Products
Same Skeleton Products
Historical Records
; ;